ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 119,61
0,30%
Dow Jones
39 069,59
0,01%
DAX
18 748,85
0,29%
Brent Oil
82,645
0,81%
Bitcoin
69 344,30
1,22%
Registration Strip Icon for discussion Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. 23andMe Holding Company (ME)

  7. 23andMe Holding Company (ME) Actualités

ME

23andMe (ME)

23andMe Holding Company
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:ME
DateHeureSourceTitreSymboleSociété
24/05/202422h06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ME23andMe Holding Company
23/05/202423h15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ME23andMe Holding Company
23/05/202422h05GlobeNewswire Inc.23andMe Reports Fourth Quarter and Full Year Fiscal 2024 Financial ResultsNASDAQ:ME23andMe Holding Company
14/05/202413h00GlobeNewswire Inc.Lemonaid Health Now Offers Prescription ED Medication STENDRAⓇ Through Collaboration with Petros PharmaceuticalsNASDAQ:ME23andMe Holding Company
09/05/202422h50GlobeNewswire Inc.23andMe to Report Q4 and Full Year FY2024 Financial ResultsNASDAQ:ME23andMe Holding Company
30/04/202417h00Business WirePotter Handy Law Firm Represents Nearly 5,000 Clients in 23andMe Data Breach CaseNASDAQ:ME23andMe Holding Company
24/04/202422h05GlobeNewswire Inc.23andMe to Present Preliminary Efficacy and Biomarker Data for 23ME-00610 at the 2024 American Society of Clinical Oncology (ASCO) Annual MeetingNASDAQ:ME23andMe Holding Company
18/04/202414h00GlobeNewswire Inc.23andMe announces CEO’s intention to pursue a potential take-privateNASDAQ:ME23andMe Holding Company
05/04/202422h05GlobeNewswire Inc.23andMe to Present Data on Two Clinical Stage Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting 2024NASDAQ:ME23andMe Holding Company
20/03/202412h30GlobeNewswire Inc.23andMe Initiates Phase 1 Clinical Trial for its Dual Mechanism Antibody, 23ME-01473, Targeting ULBP6NASDAQ:ME23andMe Holding Company
19/03/202413h00GlobeNewswire Inc.23andMe Launches New Feature Connecting Customers to Historical Individuals from Hundreds and Even Thousands of Years AgoNASDAQ:ME23andMe Holding Company
06/03/202413h30GlobeNewswire Inc.23andMe Launches New Genetic Reports on Common Forms of CancerNASDAQ:ME23andMe Holding Company
05/03/202422h30GlobeNewswire Inc.23andMe Announces Three Presentations from Clinical-Stage Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting 2024NASDAQ:ME23andMe Holding Company
07/02/202422h07Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ME23andMe Holding Company
07/02/202422h01GlobeNewswire Inc.23andMe Reports Third Quarter Fiscal 2024 Financial ResultsNASDAQ:ME23andMe Holding Company
06/02/202413h00Business WireMoneta Gold and Nighthawk Gold Complete At-Market Merger to form STLLR Gold Inc.NASDAQ:ME23andMe Holding Company
31/01/202404h12GlobeNewswire Inc.23andMe Launches Month-Long Initiative to Amplify ARRAY’s “Seat16” Program for Acclaimed Film ORIGIN by Ava DuVernayNASDAQ:ME23andMe Holding Company
30/01/202423h00Business WireNighthawk Gold Obtains Final Court Order for the Proposed ArrangementNASDAQ:ME23andMe Holding Company
24/01/202422h05GlobeNewswire Inc.23andMe to Report FY2024 Third Quarter Financial ResultsNASDAQ:ME23andMe Holding Company
22/01/202414h00Business WireMoneta Gold and Nighthawk Gold Announce the Proposed Directors for the MergeCo BoardNASDAQ:ME23andMe Holding Company
19/12/202314h00GlobeNewswire Inc.23andMe announces further expansion of 23ME-00610 Phase 1/2a clinical trial in advanced neuroendocrine and ovarian cancer patient cohortsNASDAQ:ME23andMe Holding Company
01/12/202322h06Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:ME23andMe Holding Company
28/11/202313h15Business WireNighthawk and Moneta Announce At-Market Merger to Create a Leading Canadian Gold Development CompanyNASDAQ:ME23andMe Holding Company
08/11/202322h05GlobeNewswire Inc.23andMe Reports Second Quarter Fiscal 2024 Financial ResultsNASDAQ:ME23andMe Holding Company
07/11/202314h00GlobeNewswire Inc.23andMe Launches Total Health™, its Comprehensive, Prevention-Based Health MembershipNASDAQ:ME23andMe Holding Company
06/11/202314h00GlobeNewswire Inc.23andMe Announces Updated Safety and Preliminary Efficacy Data From the Phase 1/2a Study of 23ME-00610, an Investigational Antibody Targeting CD200R1NASDAQ:ME23andMe Holding Company
31/10/202313h00GlobeNewswire Inc.23andMe Launches Health Action Plan to Provide Personalized Recommendations Based on Genetic and Other Health DataNASDAQ:ME23andMe Holding Company
30/10/202313h00GlobeNewswire Inc.23andMe Announces Collaboration Extension with a New Data Licensing Agreement with GSKNASDAQ:ME23andMe Holding Company
25/10/202322h05GlobeNewswire Inc.23andMe to Report FY2024 Second Quarter Financial ResultsNASDAQ:ME23andMe Holding Company
27/09/202322h05GlobeNewswire Inc.23andMe Announces Poster Presentations on 23ME-00610, an Investigational Antibody Targeting CD200R1, at The Society for Immunotherapy of Cancer’s (SITC) 2023 Annual MeetingNASDAQ:ME23andMe Holding Company
 Showing the most relevant articles for your search:NASDAQ:ME

Dernières Valeurs Consultées

EU
VIV
Vivendi
EU
BEL20
Bel 20
EU
RI
Pernod Ricard
EU
CAP
Capgemini
EU
CS
Axa
FTSE
UKX
FTSE 100
USI
USTECH100
US Tech 100
NYSE
MRK
Merck
EU
ML
Michelin
EU
SGO
Cie de SaintGobain
SPI
SP500
S&P 500
NYSE
MCD
McDonalds
EU
ACA
Credit Agricole
NASDAQ
AMZN
Amazon.com
COIN
ETHUSD
Ethereum
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés